An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension

NCT01281306 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

910

Enrollment

INDUSTRY

Sponsor class

Conditions

Systolic Hypertension

Interventions

DRUG: LCZ696
DRUG: Valsartan
DRUG: AHU377
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals